Synovial Sarcoma Pipeline Gains Momentum: 15+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight's, "Synovial Sarcoma Pipeline Insight, 2026" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Synovial Sarcoma pipeline landscape. It covers the Synovial Sarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Synovial Sarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Synovial Sarcoma Research. Learn more about our innovative pipeline today! @ https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Synovial Sarcoma Pipeline Report
• In April 2026- USWM CT, LLC initiated a clinical trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.
• In February 2026- Advenchen Laboratories, LLC conducted a phase III study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride in the treatment of metastatic or advanced alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS), and synovial sarcoma (SS). All participants with ASPS will receive open-label AL3818. In participants with LMS or SS, AL3818 will be compared to IV dacarbazine. Two-thirds of the participants will receive AL3818, one-third of the participants will receive IV dacarbazine.
• In February 2026- Takara Bio Inc. announced a study is to verify the safety and the efficacy of TBI-1301 for NY-ESO-1 expressing synovial sarcoma when administered following cyclophosphamide/fludarabine pre-treatment.
• DelveInsight's Synovial Sarcoma pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Synovial Sarcoma treatment.
• The leading Synovial Sarcoma Companies such as Advenchen Laboratories, Ipsen, OncoTherapy Science, C4 Therapeutics, Takara Bio, BioAtla, Inc., Immatics Biotechnologies GmbH, Sapience Therapeutics, PharmaMar and others.
• Promising Synovial Sarcoma Pipeline Therapies such as TBI-1301, Cyclophosphamide, AL3818, Dacarbazine, Sorafenib and Dacarbazine, Soblidotin, Doxorubicin, APX005M, Pazopanib and others.

Stay informed about the cutting-edge advancements in Synovial Sarcoma treatments @ https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Synovial-Sarcoma Overview
Synovial sarcoma is a rare type of soft tissue sarcoma that arises primarily around joints, often affecting the arms or legs, though it can occur in other parts of the body as well. Despite its name, it does not originate from synovial tissue (the tissue lining joints) but tends to develop in areas near joints or tendons. The exact cause of synovial sarcoma remains unclear, though genetic mutations, particularly a specific translocation between chromosomes X and 18 (t(X;18)), play a crucial role in its development. This fusion gene, SS18-SSX, drives abnormal cell growth and differentiation, contributing to tumor formation.

Synovial Sarcoma Emerging Drugs Profile
• AL3818: Advenchen Laboratories
Anlotinib (AL3818) is a novel oral receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 and 3, fibroblast growth factor 1-4, platelet-derived growth factor receptor α and β, c-Kit and Ret. Anlotinib exerts inhibitory effects on tumor growth and angiogenesis. Anlotinib has encouraging efficacy and a manageable and tolerable safety profile in a broad range of malignancies, including medullary thyroid cancer, renal cell cancer, gastric cancer and esophageal squamous cell carcinoma. Currently, the drug is in the Phase III stage of its development for the treatment of Synovial sarcoma.

• Tazemetostat: Ipsen
Tazemetostat is a first-in-class, oral small molecule inhibitor of the epigenetic enzyme EZH2. It is one of the histone methyltransferases in the epigenetics-related protein group, and is thought to regulate the expression of cancer-related genes and suppress the growth of cancer cells by specifically targeting EZH2, which contributes to the cancer growth process. Eisai holds the rights for development and commercialization of tazemetostat in Japan, where it was approved for the indication of "relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard treatment is not applicable)" in 2021, and manufactures and distributes the product. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of synovial sarcoma.

• DS-2243a: Daiichi Sankyo
DS-2243a is an investigational bispecific T-cell engager (BiTE) developed by Daiichi Sankyo, currently being studied for the treatment of advanced synovial sarcoma. This agent is designed to target tumors that express the HLA-A2 molecule and the cancer-testis antigen NY-ESO, both of which are commonly found in synovial sarcoma cells. By binding to both the tumor antigen and cytotoxic T lymphocytes, DS-2243a aims to direct the patient's immune system specifically against synovial sarcoma cells, potentially improving the body's ability to recognize and kill these cancerous cells. The ongoing Phase I clinical trial is focused on evaluating the safety, tolerability, and initial signs of efficacy of DS-2243a in patients with advanced synovial sarcoma who have limited treatment options.

The Synovial Sarcoma Pipeline Report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Synovial Sarcoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Synovial Sarcoma Treatment.
• Synovial Sarcoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Synovial Sarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Synovial Sarcoma market.

Learn more about Synovial Sarcoma Drugs opportunities in our groundbreaking Synovial Sarcoma research and development projects @ https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Synovial Sarcoma Companies
Advenchen Laboratories, Ipsen, OncoTherapy Science, C4 Therapeutics, Takara Bio, BioAtla, Inc., Immatics Biotechnologies GmbH, Sapience Therapeutics, PharmaMar and others.

Synovial-Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Synovial Sarcoma Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Stay informed about how we're transforming the future of oncology @ https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Synovial Sarcoma Pipeline Report
• Coverage- Global
• Synovial Sarcoma Companies- Advenchen Laboratories, Ipsen, OncoTherapy Science, C4 Therapeutics, Takara Bio, BioAtla, Inc., Immatics Biotechnologies GmbH, Sapience Therapeutics, PharmaMar and others.
• Synovial Sarcoma Pipeline Therapies- TBI-1301, Cyclophosphamide, AL3818, Dacarbazine, Sorafenib and Dacarbazine, Soblidotin, Doxorubicin, APX005M, Pazopanib and others.
• Synovial Sarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Synovial Sarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of Synovial Sarcoma Pipeline on our website @ https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Synovial Sarcoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Synovial Sarcoma- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. AL3818: Advenchen Laboratories
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. Tazemetostat: Ipsen
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. DS-2243a: Daiichi Sankyo
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Synovial Sarcoma Key Companies
21. Synovial Sarcoma Key Products
22. Synovial Sarcoma- Unmet Needs
23. Synovial Sarcoma- Market Drivers and Barriers
24. Synovial Sarcoma- Future Perspectives and Conclusion
25. Synovial Sarcoma Analyst Views
26. Synovial Sarcoma Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.